U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation

Patent 5877210 Issued on March 2, 1999. Estimated Expiration Date: Icon_subject March 2, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Vanadyl organo-mineral compound, method for obtaining such a compound, pharmaceutical composition containing this organo-mineral compound
Patent #: 5023358
Issued on: 06/11/1991
Inventor: Lazaro, et al.

Vanadyl organo-mineral compound, method for obtaining such a compound, pharmaceutical composition containing this organo-mineral compound Patent #: 5175001
Issued on: 12/29/1992
Inventor: Lazaro, et al.

Inventor

Assignee

Application

No. 465813 filed on 06/05/1995

US Classes:

514/492, Heavy metal containing DOAI424/178.1, CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL424/179.1, Conjugated via claimed linking group, bond, chelating agent, or coupling agent (e.g., conjugated to proteinaceous toxin via claimed linking group, bond, coupling agent, etc.)424/181.1, Conjugated to nonproteinaceous bioaffecting compound (e.g., conjugated to cancer-treating drug, etc.)435/184, Enzyme inactivation by chemical treatment435/244, Chemical stimulation of growth or activity by addition of chemical compound which is not an essential growth factor; stimulation of growth by removal of a chemical compound556/1, HEAVY METAL CONTAINING (e.g., Ga, In or T1, etc.)556/42, Vanadium, niobium, or tantalum containing (V, Nb, or Ta)556/44The metal is bonded directly to X of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens (e.g., vanadyl xanthate, etc.)

Examiners

Primary: Achutamurthy, Ponnathapu
Assistant: Ponnaluri, P.

Attorney, Agent or Firm

Foreign Patent References

  • WO 93/06811 WO. 04/13/1993

International Classes

A01N 055/02
A61K 039/395
C07F 053/00

Abstract

A method of inhibiting the proliferation of B cells by using inhibitors of phosphotyrosine phosphatase can be used to regulate the immune response and to treat diseases such as leukemias or lymphomas marked by malignant proliferation of B cells or T cells. Antitumor activity is seen in vivo against tumors and against tumor cell lines. The use of such inhibitors can be combined with radiation, which produces a synergistic effect. Several types of inhibitors can be used, including: (1) compounds comprising a metal coordinate-covalently bound to an organic moiety that can form a five- or six-membered ring, in which the metal is preferably vanadium (IV); (2) compounds in which vanadium (IV) is coordinate-covalently bound to an organic moiety such as a hydroxamate, ଱-hydroxypyridinone, ଱-hydroxypyrone, ଱-amino acid, hydroxycarbonyl, or thiohydroxamate; (3) coordinate-covalent complexes of vanadyl and cysteine or a derivative thereof; (4) nonhydrolyzable phosphotyrosine phosphatase analogues; (5) dephostatin; (6) 4-(fluoromethyl)phenyl phosphate and esterified derivatives; and (7) coordinate-covalent metal-organic compounds containing at least one oxo or peroxo ligand bound to the metal, in which the metal is preferably vanadium (V), molybdenum (VI), or tungsten (VI). Methods of stimulating signaling in T cells and conjugates of a modulator of phosphotyrosine metabolism with a specific binding partner for a B cell surface antigen are also disclosed.

Other References

  • G.J.V. Nossal, "Cellular Mechanisms of Immunologic Tolerance", Annu. Rev. Immunol. 1:33-62 (1983)
  • F.M. Uckun & J.A. Ledbetter, "Immunobiologic Differences Between Normal and Leukemic Human Cell Precursors", Proc.Natl.Acad.Sci.USA 85: 8603-8607 (1988)
  • T.R. Burke et al., "Preparation of Fluoro-and Hydroxy-4-(Phosphonomethyl)-D,L-Phenylalanine Suitably Protected for Solid-Phase Synthesis of Peptides Containing Hydrolytically Stable Analogues of O-Phosphotyrosine", J.Org.Chem. 48: 1336-1340 (1993)
  • D.B.A. de Bont et al., "Solid-Phase Synthesis of O-Phosphorothioylserine-and Threonine-Containing Peptides as Well as of O-Phosphoserine-and-Theronine-Containing Peptides", J. Org. Chem. 58: 1309-1317 (1993)
  • K. Guan et al., "A Tyr/Ser Protein Phosphatase Encoded by Vaccinia Virus", Nature 350: 359-362 (1991)
  • D. Dailey et al., "Novel Yeast Protein Kinae (YPK1 Gene Product) Is a 40-Kilodalton Phosphotyrosyl Protein Associated with Protein-Tyrosine Kinase Activity", Mol. Cell. Biol. 10: 6244-6256 (1990)
  • M. Imoto et al., "Dephostatin, a Novel Protein Tyrosine Phosphatase Inhibitor Produced by Streptomyces. I. Taxonomy, Isolation, and Characterization", J. Antibiotics 46: 1342-1346 (1993)
  • J. H. McNeill et al., "Bis(maltolato) oxovanadium (IV) Is a Potent Insulin Mimic", J.Med.Chem. 35: 1489-1491 (1992)
  • R.R. Bartlett et al., Leflunomide (HWA 486), a Novel Immunomodulating Compound for the Treatment of Autoimmune Disorders and Reactions Leading to Transplantation Rejection, Agents & Actions 32: 10-21 (1991)
  • J.K. Myers & T.S. Widlanski, Mechanism-Based Inactivation of Prostatic Acid Phosphatase, Science 262: 1451-1453 (1993)
  • L.B. Justement et al., "Regulation of B Cell Antigen Receptor Signal Transduction and Phosphorylation of CD45", Science 252: 1839-1842, (1991)
  • M.R. Gold et al, "Stimulation of Protein Tyrosine Phosphorylation by the B-Lymphocyte Antigen Receptor", Nature 345: 810-843 (1990)
  • M.C. Cam et al., "In Vivo Antidiabetic Actions of Naglivan, An Organic Vanadyl Compound in Streptozotocin-Induced Diabetes", Diabetes Res. & Clin. Pract. 20: 111-121 (1993)
  • A.L. Burkhardt et al., "Anti-Immunoglobulin Stimulation of B Lymphocytes Activates src-Related Protein-Tyrosine Kinases," Proc. Natl. Acad. Sci. USA 88: 7410-7414 (1991)
  • F.M. Uckun et al., "Tyrosine Phosphorylation Is a Mandatory Proximal Step in Radiation-Induced Activation of the Protein Kinase C Signaling Pathway in Human B-Lymphocyte Precursors," Proc. Natl. Acad. Sci. USA 90: 252-256 (1993)
  • C.P. Stewart & A.L. Prote, "Electron Paramagnetic Resonance Spectra of Some Oxovanadium (IV) Chelates," J. Chem. Soc. Dalton Trans. 1661-1666 (1972)
  • X.-R. Yao & D.W. Scott, "Expression of Protein Tyrosine Kinases in the Ig Complex of Anti-μ-Sensitive and Anti-μ-Resistant B-Cell Lymphomas: Role of the p55blk Kinase in Signalling Growth Arrest and Apoptosis," Immunol. Rev. 132: 163-186 (1993)
  • X.-R. Yao & D.W. Scott, "Antisense Oligodeoxynucleotidase to the blk Tyrosine Kinase Prevent Anti-μ-Chain-Mediated Growth Inhibition and Apoptosis in a B-Cell Lymphoma," Proc. Natl. Acad. Sci. USA 90: 7946-7950 (1993)
  • F.M. Uckun et al., "Ionizing Radiation Stimulates Unidentified Tyrosine-Specific Protein Kinases in Human B-Lymphocyte Precursors, Triggering Apoptosis and Clonogenic Cell Death," Proc. Natl. Acad. Sci. USA 89: 9005-9009 (1992)
  • P.J.L. Lane et al., "The Role of Tyrosine Phosphorylation in Signal Transduction Through Surface Ig in Human B Cells," J. Immunol. 146: 715-722 (1991)
  • F.M. Uckun et al., "Use of Novel Colony Assay to Evaluate the Cytotoxicity of an Immunotoxin Containing Pokeweed Antiviral Protein Against Blast Progenitor Cells Freshly Obtained from Patients with Common B-Lineage Acute Lymphoblastic Leukemia," J. Exp. Med. 163; 347-368 (1986)
  • M.A. Campbell & B.M. Sefton, "Protein Tyrosine Phosphorylation is Induced in Murine B Lymphocytes in Response to Stimulation with Anti-Immunoglobulin," EMBO J. 9: 2125-2131 (1990)
  • Abstract, Meeting of the Oxygen Society, Charleston, South Carolina, on Nov. 12-17, 1993, by G.L. Schieven, et al., entitled "Identification of Reactive Oxygen Intermediate Responsive Tyrosine Kinases in Lymphocytes"
  • Abstract, Ninth International Symposium on Cellular Endocrinology: "Cell Signalling and the Molecular Stress Response", Lake Placid, New York, Sep. 23-26, 1993, by G.L. Schieven et al., entitled Identification of Reactive Oxygen Intermediate Responsive Tyrosine Kinases in Lymphocytes
  • A. Shaver et al., "Insulin-Mimetic Peroxovanadium Complexes: Preparation and Structure of Potassium Oxodiperoxo (pyridine-2-carboxylato)vanadate(V), K2 ›VO(O2)2 (C5 H4 NCOO)!.2H2 O, and Potassium Oxidiperoxo (3-hydroxypyridine-2-carboxylato) vanadate(V), K2 ›VO(O2)2 (OHC5 H3 NCOO)!.3H2 O, and Their Reactions with Cysteine," Inorg. Chem. 32: 3109-3113 (1993)
  • J.P. Secrist et al., "Stimulatory Effects of the Protein Tyrosine Phosphatase Inhibitor, Pervanadate, on T-Cell Activation Events," J. Biol. Chem. 268:5886-5893 (1993)
  • F.M. Uckun et al., "Biotherapy of B-Cell Precursor Leukemia by Targeting Genistein to CD19-Associated Tyrosine Kinases," Science 267: 886-891 (1995
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?